US44975P1030 - IMAB - A2PVC6 (XNAS)
I-MAB - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
1,13 USD
Aktuelle Kurse von I-MAB - AMERICAN DEPOSITARY SHARES
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
IMAB
|
USD
|
19.09.2024 18:25
|
1,13 USD
| 1,09 USD | 3,61 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
3,61 % | 8,59 % | -3,06 % | -36,20 % | -37,61 % | -14,45 % | -90,97 % |
Firmenprofil zu I-MAB - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Investierte Fonds
Folgende Fonds haben in I-MAB - AMERICAN DEPOSITARY SHARES investiert:
Fonds | Vol. in Mio 75,32 | Anteil (%) 0,18 % |
Fonds | Vol. in Mio 2,68 | Anteil (%) 0,08 % |
Fonds | Vol. in Mio 110,45 | Anteil (%) 0,04 % |
Fonds | Vol. in Mio 465,11 | Anteil (%) 0,04 % |
Fonds | Vol. in Mio 7,88 | Anteil (%) 0,04 % |
Unternehmensdaten I-MAB - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
Name I-MAB - AMERICAN DEPOSITARY SHARES
Firma I-Mab
Symbol IMAB
Website https://www.i-mabbiopharma.com
Heimatbörse
NASDAQ
WKN A2PVC6
ISIN US44975P1030
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Dr. Xi-Yong Fu M.B.A., Ph.D.
Marktkapitalisierung 91 Mio
Land China
Währung USD
Mitarbeiter 0,2 T
Adresse New Bund Center, 200124 Shanghai
IPO Datum 2020-01-17
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 0VY.F |
NASDAQ | IMAB |
Weitere Aktien
Investoren die I-MAB - AMERICAN DEPOSITARY SHARES halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024